Journal
JOURNAL OF NEUROLOGY
Volume 268, Issue 6, Pages 2284-2292Publisher
SPRINGER HEIDELBERG
DOI: 10.1007/s00415-020-10349-w
Keywords
Ischemic stroke; Cardiac biomarker; Stroke-heart-syndrome; Cardiac troponin; Brain– heart interaction; Myocardial injury; Myocardial infarction
Categories
Funding
- Projekt DEAL
Ask authors/readers for more resources
Cardiac troponin is a useful biomarker for identifying and quantifying myocardial injury, which is often detected after acute ischemic stroke. However, uncertainty exists regarding the interpretation and management of elevated cardiac troponin levels in stroke patients. 'Stroke-Heart Syndrome' encompasses a range of cardiac complications after stroke, including injury, dysfunction, and arrhythmia.
Cardiac troponin is a specific and sensitive biomarker to identify and quantify myocardial injury. Myocardial injury is frequently detected after acute ischemic stroke and strongly associated with unfavorable outcomes. Concomitant acute coronary syndrome is only one of several possible differential diagnoses that may cause elevation of cardiac troponin after stroke. As a result, there are uncertainties regarding the correct interpretation and optimal management of stroke patients with myocardial injury in clinical practice. Elevation of cardiac troponin may occur as part of a 'Stroke-Heart Syndrome'. The term 'Stroke-Heart Syndrome' subsumes a clinical spectrum of cardiac complications after stroke including cardiac injury, dysfunction, and arrhythmia which may relate to disturbances of autonomic function and the brain-heart axis. In this review, we provide an up-to-date overview about prognostic implications, mechanisms, and management of elevated cardiac troponin levels in patients with acute ischemic stroke.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available